On This Day in Health: April 6, 2017
On April 6, 2017, the U.S. Food and Drug Administration authorized 23andMe to market the first direct-to-consumer tests providing genetic health risk information for certain conditions. The decision covered reports about ten diseases or conditions, including late-onset Alzheimer’s disease, Parkinson’s disease, hereditary hemochromatosis and celiac disease. Adults could send a saliva sample for analysis and receive information about selected genetic variants associated with increased risk. The authorization opened a new route to personal genetic information outside a traditional clinic visit. It also established an important distinction: learning about a genetic risk factor is different from receiving a diagnosis or a complete prediction of future health.
The test examined particular variants rather than every possible cause of each condition. Some reports concerned inherited disorders; others addressed conditions shaped by both genes and environmental factors. A result indicating increased genetic risk did not mean that a person would necessarily develop the disease. A result without the tested variants did not establish that the person had no risk. Family history, age, lifestyle and other biological factors could remain important. The FDA also noted that the association between a variant and a condition could differ across populations. These limitations made the explanation accompanying a report as consequential as the laboratory’s ability to detect a variant.
The agency reviewed analytical performance, the relationship between the selected variants and health risks, and whether consumers could understand the reports. It established special controls for this category of device, including requirements addressing accuracy and user comprehension. Those safeguards reflected the unusual setting: people would encounter potentially consequential health information directly, sometimes without a clinician present to explain it. The FDA cautioned that results should not be the sole basis for medical decisions and that consumers should discuss questions with a health professional. The authorization did not make the reports a substitute for a clinical evaluation, nor did it approve using them alone to start, stop or alter treatment.
April 6 marked a shift in how genetic knowledge could enter everyday life. Earlier consumer testing had included ancestry information and certain carrier-status reports, but this decision addressed personal health risk reports for the specified conditions. The appeal was clear: a small saliva sample could reveal information previously encountered mainly through medical genetics services. The challenge was equally clear: useful access depended on an accurate understanding of what the information could and could not establish. The milestone therefore belongs to both the history of biotechnology and the history of health communication. It expanded access while making uncertainty, informed interpretation and appropriate follow-up central to the value of the result.
The FDA authorized the first direct-to-consumer genetic health risk reports on April 6, 2017.
The decision covered ten specified diseases or conditions.
The reports used selected genetic variants detected in a saliva sample.
Genetic risk information did not constitute a diagnosis or a complete measure of risk.
The FDA evaluated accuracy and consumers’ understanding of the reports.
Medical decisions required broader clinical information and appropriate professional discussion.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.